Endocrine cancer review.

Revista Romana de Medicina de Laborator

One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase.

They change related to the disease progression, regardless therapy. Some of the cancerul si alimentatia that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose metabolism.

We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile. Material and Methods. All the patients had at least one assay per year.

endocrine cancer review

The dose endocrine cancer review octreotide varied from endocrine cancer review to 50 mg, monthly. The fasting glucose insignificantly changed from baseline after 2 years.

No new case of diabetes was registered. One case of known diabetes needed insulin but endocrine cancer review therapy was also added during this endocrine cancer review period.

The chromogranin A had sustained high values for all the 9 cases, marking the disease progression. The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 cases with aggressive carcinoid symptoms. The NET markers and the glucose metabolism are most useful tools in the management of NETs, endocrine cancer review they are not correlated. Rezumat Tumorile neuroendocrine NET sunt mult mai frecvente în ultimele decade.

Unul din intrumentele majore de evaluare în această patologie este reprezentat de dozarea markerilor neuroendocrini precum cromogranina A, serotonina, acidul 5-hidroxi indolacetic urinar şi enolaza neuronal specifică. Aceştia se schimbă cu progresia tumorală, indiferent de terapie.

papilloma virus vaccinare o no pancreatic cancer vegan

O parte din medicamentele folosite în NET precum analogii de somatostatin de exemplu, octreotid interferă cu metabolismul glucozei. Am analizat într-un studiu retrospectiv de-a lungul a 2 ani dinamica markerilor NET şi profilul glicemic.

Material si metode. Toţi pacienţii au avut cel puţin o evaluare pe an.

Most Downloaded Articles

Doza de octreotid a variat de la 20 la 50 mg lunar. Glicemia s-a modificat nesemnificativ de la bază după 2 ani. Nu s-a înregistrat nici un caz nou de diabet. O pacientă a necesitat insulină pentru diabetul preexistent dar între timp s-a adaugat şi terapie cu interferon Cromogranina A a avut valori mari sustinute pentru endocrine cancer review cele 9 cazuri, sugerând progresia bolii.

Enolaza neuronal specifică a crescut semnificativ iar serotonina endocrine cancer review şi 5HIIA au crescut considerabil în 2 cazuri cu simptome severe de sindrom carcinoid.

Markerii NET şi metabolismul glucidic sunt instrumente foarte utile in managementul tumorilor neuroendocrine, totusi acestea nu se coreleaza. Cuvinte cheie: cromogranina A ; tumora neuroendocrina ; serotonina References 1. Neuroendocrine tumors.

Endocr Relat Cancer. DOI: Oberndorfer S. Karzinoide tumoren des dunndarms. Frank Z Pathol. Google Scholar 3. Carcinoid Tumors. Bellizzi AM.

Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of endocrine cancer review immunohistochemistry. Adv Anat Pathol. Chromogranins A, B, C: widespread consitituents of secretory vesicles. Ann N Y Acad Sci. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.

cancer de prostata laboratorio

Regul Pept. The poor prognosis factors in G2 neuroendocrine tumor. Rom J Morphol Embryol. Google Scholar The dedifferentiation of neuroendocrine tumor metastases: myth or reality? PubMed Google Scholar Octreotide for the treatment of hypoglycemia after insulin glargine overdose. J Emerg Med. Biochemical testing for neuroendocrine tumors. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am ;40 1 Well-differentiated neuroendocrine tumor and osteoporosis: incidental finding?

Archive of Clinical Cases

Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol.

endocrine cancer review

Long-term clinical outcome of somatostatin analogues for treatment of pregressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol.

endocrine cancer review

Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.

Citițiși